Measurable Kidney-Sparing Care Pathway: How to Make a CO₂/Contrast-Sparing Pathway Audit-Ready

Kidney-sparing care pathway projects (pathways designed to reduce renal injury associated with procedures involving contrast media) often fail not because of the clinical rationale, but because of a lack of measurability. This content is intended for Hospital Management, Clinical Governance teams, and vascular teams seeking to reduce AKI and CIN (acute kidney injury and contrast-induced nephropathy), length of stay, and readmissions in a defensible manner. Without selection criteria and a minimum data set, the assessment remains open to interpretation and cannot be scaled.

Why a kidney-sparing project can be clinically sound yet “weak” from a Hospital Management perspective

During technology committee or HTA (Health Technology Assessment) meetings, the issue is not “whether CO₂ works,” but whether a standardized pathway is in place that allows outcomes to be attributed to reproducible decisions. Hospital Management evaluates indicators such as complications, days in hospital, readmissions, appropriateness, and risk. If each operator makes decisions “case by case” without traceability, the project cannot be audited and cannot become a network-wide integrated diagnostic, therapeutic, and care pathway.

In other words, the technology may be promising, but without a measurable protocol, the question remains: what have we actually changed, and how can we demonstrate it?

What AKI and CIN mean, and why measurement is the first safety measure

AKI (Acute Kidney Injury) is an acute deterioration in kidney function, typically assessed using serum creatinine and urine output over a 48–72-hour period following a clinical event. CIN (Contrast-Induced Nephropathy) is a term historically used to describe renal injury following exposure to iodinated contrast media. Today, many scientific societies prefer concepts such as “contrast-associated” AKI because the causal relationship depends on the clinical context.

From a governance perspective, however, the practical point is straightforward: unless the method used to measure AKI and the relevant time windows are defined, nothing can be compared. As a result, even a genuine improvement may not be reflected in the data, causing the project to stall.

The most common gap: no care pathway with patient and procedure selection criteria

Many kidney-sparing programs originate from complex cases involving patients with CKD, diabetes, or an allergy to iodinated contrast media, and then grow opportunistically. In committee discussions, however, the first objection is legitimate: to whom does the pathway apply, according to which thresholds, such as eGFR, and for which procedures, such as below-the-diaphragm peripheral procedures, selected EVAR/FEVAR cases, or revascularizations?

eGFR (estimated Glomerular Filtration Rate) is an estimate of glomerular filtration and a summary indicator of kidney function used in daily practice. An effective care pathway explicitly defines how eGFR informs patient selection, together with clinical factors such as age, diabetes, hypovolemia, nephrotoxic medications, and hemodynamic instability, as well as the imaging strategy.

The second gap: incomplete and non-comparable data (residual iodine, procedural parameters, and outcomes)

A contrast-sparing project can only be evaluated when it tracks both inputs (what was done) and outputs (what happened to the patient). Without a minimum data set, the outcome of the committee review is predictable: the decision is postponed, “more local evidence” is requested, or the project is confined to a pilot that cannot be scaled.

The minimum data set should include both clinical and process data. The following deliberately concise operational example makes the pathway comparable across teams and over time:

• Inclusion criteria: eGFR, history of AKI, diabetes, allergy to iodinated contrast media, emergency or elective status, and procedure type.
• Iodinated contrast exposure: total volume (mL) and “residual iodine” when a combined strategy is used.
• Traceable procedural parameters: use of CO₂ (yes/no), protocols and key settings, and any conversion to iodinated contrast with the reason documented.
• Renal outcomes: AKI according to a pre-specified definition (e.g., KDIGO), change in creatinine at 48–72 hours, and need for dialysis.
• Operational outcomes: LOS (Length of Stay), 30-day readmissions, and major complications.

These elements transform a “good clinical idea” into an audit-ready project because they make it possible to distinguish among patient selection, adherence to the pathway, and outcomes.

Kidney-sparing care pathways and CO₂: linking workflow standardization to measurable outcomes

CO₂ has been used as a contrast agent in peripheral angiography for years to reduce exposure to iodinated contrast in vulnerable patients. However, committees also assess operator-dependent variability and organizational risk. This is where workflow standardization makes a difference: repeatable protocols, traceability, and training reduce heterogeneity and make the data comparable.

An automatic digital CO₂ injector, such as those developed by Angiodroid for below-the-diaphragm angiography, shifts the project from a “technique” to a “pathway”: parameters are more controlled, dedicated consumables are used, and there is a greater ability to document what was done. Technology alone is not enough. A care pathway must define when the technology should be used, how data should be recorded, and how exceptions should be managed.

Team training: the element that makes the care pathway scalable, not merely the first successful case

Training is a quality measure, not an “optional extra.” A CO₂/contrast-sparing pathway becomes scalable when the entire team—vascular surgery, interventional radiology, anesthesia, nursing, and nephrology—shares the same criteria, terminology, and monitoring objectives. In practice, training reduces the risk of unjustified deviations and improves the quality of the data collected.

From the perspective of Hospital Management, structured training is also a form of governance: it makes it possible to define competencies, supervised training periods, qualification criteria, and a continuous-improvement plan based on periodic audits.

How to present a defensible kidney-sparing project to a committee: from the clinical case to the business case

During committee review, the implicit question is: what changes for patients and the hospital, and how will it be measured? A measurable care pathway answers this question with clear KPIs (indicators) and a baseline. The process begins with historical data, such as post-procedure AKI, average iodinated contrast volume, LOS, and readmissions. A defined scope is then established—for example, peripheral procedures in patients with an eGFR below a specified threshold—and a pilot period is set up with an audit at three to six months.

This approach links the technology decision to clinical outcomes and sustainability: fewer AKI events often mean fewer complications, more predictable care pathways, and better bed management. The objective is not to promise “zero risk,” but to demonstrate a measurable and reproducible improvement.

Call to action: obtain a draft care pathway and the minimum data set for an audit-ready pilot

When evaluating a CO₂/contrast-sparing pathway, moving beyond the “we do not have enough data” impasse requires a structured approach. We can support your center with a draft kidney-sparing care pathway, a minimum audit data set, and a team training plan. The objective is to make the project ready for committee review, with its criteria, measurements, and governance already defined.

Request a technical and clinical consultation and the audit-ready care pathway checklist

Frequently Asked Questions